ZIOPHARM Oncology Inc (ZIOP) Lowered to “Sell” at ValuEngine
ValuEngine lowered shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) from a hold rating to a sell rating in a research report report published on Friday.
A number of other brokerages have also recently commented on ZIOP. HC Wainwright set a $10.00 target price on shares of ZIOPHARM Oncology and gave the company a buy rating in a report on Tuesday, August 1st. BidaskClub upgraded shares of ZIOPHARM Oncology from a sell rating to a hold rating in a report on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $13.17.
Shares of ZIOPHARM Oncology (NASDAQ ZIOP) traded up 3.67% during mid-day trading on Friday, hitting $6.21. 1,985,023 shares of the stock traded hands. The company’s 50-day moving average price is $5.82 and its 200 day moving average price is $6.25. ZIOPHARM Oncology has a 1-year low of $4.84 and a 1-year high of $7.88. The company’s market capitalization is $873.32 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. During the same quarter last year, the firm posted ($1.01) EPS. The business’s quarterly revenue was down 5.9% on a year-over-year basis. Equities research analysts forecast that ZIOPHARM Oncology will post ($0.56) EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Canada Pension Plan Investment Board purchased a new position in shares of ZIOPHARM Oncology in the 2nd quarter worth about $1,010,000. Vident Investment Advisory LLC raised its position in shares of ZIOPHARM Oncology by 20.0% in the 1st quarter. Vident Investment Advisory LLC now owns 137,976 shares of the biotechnology company’s stock worth $875,000 after purchasing an additional 22,996 shares during the last quarter. Old West Investment Management LLC purchased a new position in shares of ZIOPHARM Oncology in the 1st quarter worth about $205,000. Morgan Stanley raised its position in shares of ZIOPHARM Oncology by 19.5% in the 1st quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock worth $12,610,000 after purchasing an additional 324,774 shares during the last quarter. Finally, Teachers Advisors LLC raised its position in shares of ZIOPHARM Oncology by 8.3% in the 1st quarter. Teachers Advisors LLC now owns 214,906 shares of the biotechnology company’s stock worth $1,363,000 after purchasing an additional 16,398 shares during the last quarter. 41.94% of the stock is owned by hedge funds and other institutional investors.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Stock Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related stocks with our FREE daily email newsletter.